Context: GlaxoSmithKline (GSK) 2881078 is a nonsteroidal, selective androgen receptor modulator (SARM) under investigation by GSK for treatment of reduced mobility and other functional limitation in men and women with muscle weakness associated with chronic and acute illnesses.
G laxoSmithKline (GSK) 2881078 is a nonsteroidal, selective androgen receptor modulator (SARM) under investigation by GSK for treatment of reduced mobility and other functional limitation in men and postmenopausal women with muscle weakness associated with both chronic and acute illness.
SARMs bind to the androgen receptor, inducing a unique receptor conformation that allows only certain coactivator and corepressor proteins to interact. The differential activity allows SARMs to function as potent androgenic agonists in target tissues such as muscle and bone, but to function as antagonists, or partial agonists, in other tissues or organs such as the prostate or skin (1, 2) . An appropriately selective SARM has the potential to be given to postmenopausal women without inducing hirsutism or virilization, which both occur with steroidal androgen receptor modulators. The tissue selectivity of GSK2881078 was assessed in a classic Hershberger assay (3) and demonstrated anabolic responses in androgenresponsive skeletal muscles in orchiectomized rodents with reduced anabolism in other tissues compared with dihydrotestosterone GSK2881078 at 0.3 mg/kg/d dosed orally once daily for 28 days restored the weight of the levator ani muscle in orchiectomized rats to that of shamoperated rats but produced only a minor increase in prostate weight compared with vehicle-treated orchiectomized rats (unpublished data).
GSK2881078 was previously administered in a first time in human study at doses up to 0.75 mg for 14 days in healthy older male and female subjects. There appeared to be a differential dose response exhibited between males and females, indicating that females may be more sensitive to the pharmacological effects of GSK2881078 than are males. It was decided to further examine the sex-specific pharmacokinetics (PK) and pharmacodynamics (PD) of GSK2881078 in a phase 1b study across a dose range.
Methods

Study design
This phase 1b study was conducted in two parts. Part A was a randomized double-blind (sponsor unblinded), placebocontrolled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PK, and PD of repeat doses of GSK2881078. Part B was an open-label, single-sequence, two-period crossover study to evaluate the effect of CYP3A4 inhibition on PK of GSK2881078.
Part A included healthy older males and postmenopausal females, aged $50 years. Within each cohort, participants were randomized 2:1 to a single dose level of GSK2881078 or placebo. A total of six cohorts of volunteers were recruited and randomized. The first two cohorts of males and two cohorts of females were dosed for 28 days. Men and women were dosed at different dose levels. The doses for the first two cohorts of males were 0.75 mg and 1.5 mg, respectively. The doses for the first two cohorts of females were 0.5 mg and 0.75 mg, respectively. The final two cohorts, one male and one female, were dosed for a longer period of 56 days. In these final two cohorts, females received 0.35 mg of GSK2881078 daily for 28 days followed by 1.5 mg of GSK2881078 daily for an additional 28 days. This design allowed evaluation of two doses, one lower than studied before and one higher than studied before, in the same cohort. The males received a 4-mg dose of GS2881078 daily for 56 days. All doses were administered twice daily for the first 3 days followed by once daily dosing thereafter.
Participants remained resident in the clinical facility for the first 2 weeks of dosing. Thereafter, once allowed home, participants were required to abstain from strenuous physical activity and were not to initiate any new exercise regimen from screening to follow-up. For all cohorts in part A, three followup visits were conducted during a period of 2 months following the last dose to ensure subject safety.
Part B of the study evaluated the effect of CYP3A4 inhibition on the PK of GSK2881078. Part B enrolled one cohort of 15 healthy male subjects. Participants were administered a single dose of GSK2881078 0.2 mg on day 1 of period 1 and PK samples were collected during the next 28 days. Following a 2-week washout, in period 2 participants were administered a CYP3A4 inhibitor, itraconazole, 200 mg twice on day 1 followed by once daily dosing on days 2 to 34. A single dose of GSK2881078 (0.2 mg) was administered on day 6 of period 2 and PK samples were collected during the next 28 days.
The investigators and sponsor complied with all regulatory requirements relating to safety reporting to regulatory authorities, Institutional Review Boards (IRBs), and investigators. The study protocol was approved by an independent IRB (Midlands IRB, Overland Park, KS). This study was conducted in accordance with Good Clinical Practice and all applicable regulatory requirements, as well as the guiding principles of the 2008 Declaration of Helsinki. All subjects gave written informed consent before enrolment, which included compliance with the requirements and restrictions listed in the consent form.
Assessments
To evaluate safety and tolerability, clinical laboratory tests, vital signs, ECGs, physical examinations, echocardiograms, cardiac biomarkers, and cardiac telemetry were conducted, and adverse events were monitored.
To evaluate the PK profile of GSK2881078, plasma samples were collected and assayed using a validated analytical method based on protein precipitation, followed by high-performance liquid chromatography-tandem mass spectrometry/mass spectrometry analysis. The lower limit of quantification for GSK2881078 was 50 pg/mL and the higher limit was 50,000 pg/mL. Analytical computer systems included Analyst version 1.6.1 and SMS2000 version 2.3 (4) .
PK analyses of the concentration-time data for plasma GSK2881078 were conducted using noncompartmental Model 200 (for extravascular administration) Phoenix Build 6.3.0.395, WinNonlin 6.3 (Pharsight Corporation, St. Louis, MO). Model 200 is a data analysis model implemented in WinNonlin software to analyze plasma PK data obtained following oral route of administration. Actual elapsed time from dosing was used to estimate all individual plasma PK parameters for evaluable subjects. The maximum observed concentration (C max ) and the time at which C max was observed were determined directly from the raw concentration-time data. The area under the plasma concentration-time curve (AUC) over the dosing interval (AUC 0-t ) in part A and AUC from time 0 extrapolated to infinity in part B were calculated by a combination of linear and logarithmic trapezoidal methods. The linear trapezoidal method was used for all incremental trapezoids arising from increasing concentrations, and the logarithmic trapezoidal method was used for those arising from decreasing concentrations.
Assessments of lean mass accrual were made using dualenergy X-ray absorptiometry (DXA) and MRI. These were performed at baseline (up to 2 weeks prior to dosing), on days 13 to 15 (28-day regimens), 27 to 29 (all regimens), 55 to 58 (56-day regimens), and at the first follow-up visit (;2 weeks after the last dose of GSK2881078). The output from the DXA scans was used to measure body composition, including total lean body mass (tLBM) and appendicular lean body mass (aLBM). Bone density was not evaluated owing to the relatively short period of drug exposure. aLBM was calculated from the regional lean mass measurements of the arms and legs. Thigh muscle volume (TMV) with and without intramuscular fat was reported from the MRI.
Liver function tests, microRNA-122, lipids, and hormones were evaluated in plasma or serum at baseline, at multiple times during the dosing period, and at follow-up visits.
Statistical analyses
The study was not powered to evaluate any statistical hypotheses. However, consideration was given to the precision of the estimate of change from baseline tLBM. Assuming normally distributed data and an SD of 1.5 kg, eight subjects per arm would result in a CI width of 3.22 kg for the difference in mean change from baseline tLBM between an arm of GSK2881078 and placebo.
To assess safety and tolerability of GSK2881078, treatment comparisons with placebo were based on review of descriptive statistics and individual subject data. No formal statistical hypotheses were tested. An estimation approach was used to address the PK, PD, and biomarker objectives, where point estimates and corresponding CIs were constructed as appropriate. PD and biomarker endpoints were analyzed for each sex separately using mixed models repeated measures or analysis of covariance with baseline covariate. There were no adjustments for multiplicity.
In part A, dose proportionality was assessed for AUC 0-t and C max for each sex using an ANOVA model and a power model [e.g., log(AUC) = a + b 3 log(dose)]. The power model is used to model the PK-dose response relationship. The model can be written as AUC = a 3 dose b . The power model is equivalent to fitting a linear model (e.g., straight line) on the log-log scale using the following model: log(AUC) = log(a) + b 3 log(dose). The dose proportionality of the relationship can be assessed by how close or far the estimated value of b is to 1, where b = 1 reflects perfect dose proportionality (i.e., if the dose is doubled, the PK parameter will double in value). Values of b . 1 indicate greater than dose proportionality, and values of b , 1 indicate less than dose proportionality.
In part B, the effects of itraconazole on the AUC and C max of GSK2881078 were analyzed following log transformation using a mixed effects model with a fixed effect term for treatment and a random effect for subject.
Results
Demographics
Ninety-three subjects were enrolled in part A. All subjects enrolled were intentionally .50 years of age. The ethnicity of the subjects was primarily white/ European (female, 94%; male, 78%).
Fifteen male subjects were enrolled in part B. The subjects were over 18 years old and primarily white/ European (see Supplemental Material).
Pharmacokinetics
Following multiple dose administration, consistent with long half-life, C max and AUC parameter estimates increased significantly over time for both male and female subjects (Fig. 1) , with accumulation ratios on day 28 ranging from 14-to 16-fold for males and from 14-to 23-fold for females. The accumulation ratio is calculated as the ratio of drug concentrations observed during a dosing interval at steady-state divided by drug concentrations observed C max appeared to increase in a dose proportional manner for days 14 and 28 for female and male subjects. AUC 0-t increased dose proportionally for male subjects and slightly greater than dose proportionally for female subjects. The power model slope estimates and CIs generally confirmed these results.
Part B of the study showed that coadministration with a strong CYP3A4 inhibitor (itraconazole) resulted in a modest change in exposure to GSK2881078 (Supplemental Material).
Pharmacodynamics
Compared with placebo, there was found to be greater lean mass accrual across all doses of GSK2881078 (Figs. 2 and 3; Table 1 ). Findings were generally consistent between MRI and DXA. Figure 2 demonstrates dosedependent changes in aLMB, tLMB, and TMV observed after 28 days of dosing in male and female subjects. As can be seen in Fig. 2 , there was a relatively high placebo response in males that could not be explained. Figure 3 shows the time course of changes for the cohorts that received 56 days of dosing. In women, increasing the dose from 0.35 mg to 1.5 mg for an additional 28 days of dosing resulted in additional gains in lean mass ( Fig. 3 ; Table 1 ). There was an apparent increased sensitivity of women to lean mass accrual with GSK2881078. On an exposure basis, females were more sensitive to the compound than males, with day 56 aLBM gains of 1.83 kg and 1.21 kg, respectively. In men, the effect of dosing for 56 days relative to 28 days was not consistent across the three measures of lean mass, with no apparent change in aLBM, a slight gain in tLBM, and a greater increase in TMV noted with MRI.
In both male and female subjects, a dose proportional increase in exposure was observed over the dose ranges evaluated (Fig. 1) , and the exposure-response relationships appeared to be best described by a linear stimulatory relationship with change from baseline in lean mass (aLBM, tLBM, and TMV) increasing as exposure increased. Thus, within the dose range evaluated, there was an apparently linear relationship bridging dose to exposure to lean mass change from baseline.
Safety
GSK2881078 was generally well tolerated across all doses for up to 56 days, with no serious adverse events reported and no symptomatic or hormonal evidence of virilization in females reported. Potentially clinically significant changes were observed in subjects dosed with GSK2881078 in liver function tests, lipids, and testosterone.
Liver function tests
Alterations (change from baseline) were observed in liver functions tests primarily for alanine aminotransferase (ALT) and aspartate aminotransferase (data not shown); both demonstrated increases with ALT being most affected Table 2 ). Alkaline phosphatase demonstrated a tendency to decrease during dosing. Total and direct bilirubin were generally unchanged and no changes in the international normalized ratio were observed.
Elevations in ALT where they did occur were evident from approximately day 14 and were transient in nature, in most instances beginning to resolve despite continuing dosing with study drug and returning to baseline values by approximately day 28 of dosing. The elevations in ALT were considered drug-related and the incidence of elevations in ALT were similar across all doses in both females and males, with the exception of the males receiving 4 mg of GSK2881078, who had a greater incidence of ALT elevations than did other dosage groups.
A pharmacogenetic analysis (study ID 207523) was undertaken to evaluate the effects of genetic variation in the human leukocyte antigen genes, CYP3A4, and across the genome on ALT elevation observed in subjects who consented to pharmacogenetic research and were treated with GSK2881078 in the study (N = 50). No evidence was observed for genetic variation being associated with ALT elevations in subjects treated with GSK2881078 this study.
To try and understand the origins of the ALT elevation, we evaluated the plasma levels of microRNA-122, a specific intracellular hepatocellular biomarker, the presence of which is indicative of hepatic cell damage. There was found to be a positive correlation in subjects dosed with GSK20881078 between elevations in ALT and changes in plasma levels of microRNA-122. The day 29 correlation in females receiving 0.7 5 mg of GSK2881078 was 0.462 and in males receiving 1.5 mg was 0.845. Therefore, the plasma ALT is thought to indeed be hepatic in origin.
Thereafter, we employed a computational model of druginduced liver injury (DILIsym ® ) analysis of these clinical data to predict the associated hepatocyte loss. Based on this model, the hepatocyte loss in study volunteers with serum liver enzyme elevations was predicted to range from 5% to 16%. Published data suggest minimal impact on liver function when hepatocyte loss is ,25%. To put this in context, prior DILIsym ® analyses of transient ALT elevations in healthy adults treated with heparins (drugs with no history of clinically significant liver injury) predicted hepatocyte loss ,16%. Exploratory simulations based on a representative patient profile suggest that ALT elevations would need to be 5-to 10-fold higher than observed in the phase 1b trial to be at risk for serious liver injury.
Lipids
All subjects dosed with GSK2881078 exhibited a reduction in high-density lipoprotein (HDL) cholesterol ( Fig. 4 ; a similar tendency was observed across all cohorts), with a maximal reduction of ;30% to 45% from baseline observed with the highest doses of GSK2881078 in both sexes. This was accompanied by a similar proportion reduction in apolipoprotein A1 (data not shown). Per protocol, subjects were followed until any abnormal laboratory results reached baseline or were no longer considered clinically significant. For those subjects who returned for extended follow-up, HDL cholesterol returned to baseline, normal, or near normal in all cases (data not shown). Low-density lipoprotein cholesterol LS mean indicates the point estimate derived from the mixed models repeated measures model. increases of ;30% at the highest dose in males and the top two doses in females were also observed (data not shown).
Hormones
All male subjects dosed with GSK2881078 displayed reversible reductions in total testosterone. Calculated free testosterone showed a more limited decrease compared with total testosterone due to concurrent decreases in SHBG (Fig. 4) . No changes in prostate-specific antigen were recorded (data not shown). Reductions in thyroxine and thyroid-binding globulin were observed (Fig. 4) . Reversible reductions in sex hormone-binding globulin were also observed in women. There were no clinically significant changes in FSH, LH, estradiol, or progesterone (Fig. 4 and data not shown) .
Discussion
Lean mass gains
Sizeable gains in lean mass were achieved on dosing with GSK2881078 in both sexes in the absence of any resistance training. In the healthy aged volunteers studied, maximal mean tLBM change from baseline approached 1.76 kg (SE of 0.767) in males and 3.39 kg (SE of 0.406) in females after 8 weeks of treatment. Findings were generally consistent between DXA and MRI, although a higher placebo response rate was recorded in male subjects using DXA. In both male and female subjects, the effect on lean mass after 4 weeks appeared to plateau at the two highest doses.
Context of lean mass gains
To our knowledge, this is the first study to examine the dose response of lean mass accrual with a SARM over separate dose ranges in men and women. Several other SARM molecules have been tested in lean mass accrual studies but have either used a single fixed dose (5) or a range of doses that did not achieve a plateau in the PD effect (6, 7) . The absolute degree of lean mass accrual with GSK2881078 compares favorably to these studies. For example, SARM LGD-4033 was dosed up to 1 mg daily in healthy adult males for 3 weeks with a DXA measurement of lean mass at 4 weeks (6). This produced aLBM changes from baseline of 0.57 kg relative to placebo (compare to a maximal increase of 0.87 kg in males and 0.98 kg in females relative to placebo after 4 weeks of treatment with GSK20881078). By way of comparison, as assessed by MRI TMV, at the 8-week time point, 4 mg of GSK2881078 in male volunteers appeared to achieve a similar change from baseline to that reported for a 125-mg intramuscular weekly injection of testosterone at 20 weeks (8) . A comparison of these lean mass gains to those achieved through resistance exercise training in a similarly aged population is provided in the Supplemental Material.
Another significant finding from this study was the apparently increased sensitivity of women to lean mass accrual with GSK2881078 with a potential plateau in efficacy in men. On an exposure basis, females were more sensitive to the compound than males. There is also limited data that this may be the case for other SARMs also. The SARM ostarine (Gtx, Inc.) reported LBM data after 12 weeks of dosing in older men and women as a single value (7), but a later press release (9) that detailed sexspecific results also suggested greater sensitivity to lean mass accrual in women with more than twice the LBM accrual of men at 3 mg of ostarine (1.7 kg in women vs 0.7 kg in men).
A flattened dose response in men seen here is in contrast with the more linear dose response observed in men dosed with testosterone (8, 10) . PK analysis reveals no overlap in drug exposure between the 1.5-mg and 4-mg doses as shown in Fig. 1 , implying that the plateau in exposure response is genuine, albeit in a trial with small numbers of participants. One possible explanation for this could relate to the reduction in endogenous circulating testosterone seen in males, which might lower the overall anabolic effect of SARM compared with females. However, we observed a more limited decrease in calculated free testosterone during this study due to the synchronous decrease in circulating sex hormonebinding globulin. Another possibility is that GSK2881078 does not recapitulate 100% of the anabolic actions of supraphysiological doses of testosterone. In support of this, note that DHT, although having enhanced affinity for the androgen receptor compared with testosterone, is dispensable to lean mass accrual in men (11) and when supplemented alone has relatively modest effects on lean mass (12) .
Changes in liver function tests, lipids, and hormones
Potentially clinically significant changes were observed in subjects dosed with GSK2881078 across three main domains: liver function tests, lipids, and testosterone. These findings are consistent class effects with other SARMs based on the published literature (13).
Context of ALT increase
Sporadic increases in circulating ALT enzyme have been documented for at least two additional clinical stage SARM compounds (5, 7) . The cause and origin of this elevation is currently not well understood. We found no genetic phenotype or other biomarker that distinguished subjects with elevated ALT from those who remained within normal ranges.
The good positive correlation between an intracellular hepatocellular biomarker and ALT suggests that the ALT is indeed hepatic in origin, as opposed to coming from other sources. That elevations in ALT were transient in nature despite continued dosing implies that the mechanism of liver injury was not due to a direct hepatotoxicity from either GSK20881078 or one of its metabolites. One possible cause could be that a homeostatic mechanism becomes active to alter the response.
Increases in ALT were paired with elevations in aspartate aminotransferase, but of lower magnitude, possibly a reflection of the shorter serum half-life of this protein (14) . No subject demonstrated elevations of bilirubin, international normalized ratio, or alkaline phosphatase with GSK2881078, suggesting that liver damage, if present, was modest and did not impact function.
Using computational simulation (DILIsym ® ) to estimate hepatocellular damage based on the ALT profile seen in this study, apoptotic hepatocyte loss associated with the observed ALT levels was estimated to range from 5% to 16% (2% to 10% with necrotic hepatocyte loss). Literature data suggest that minimal changes in liver function are expected at these levels of hepatocyte loss. Portmann et al. (15) examined prothrombin time and peak bilirubin concentrations at different levels of viable hepatocyte fraction that were measured in liver biopsies performed on ;70 acetaminophen overdose patients. The 5% to 16% hepatocyte loss predicted for GSK2881078 patients with ALT elevations translates to ;74% to 85% viable hepatocyte volume. Within this range of viable hepatocytes, prothrombin time is likely normal to minimally prolonged. Similarly, plasma bilirubin levels within the range of estimated hepatocyte loss are much less than 2 mg/dL, which is below the plasma bilirubin level that is associated with jaundice (3 mg/dL). These data indicate a very low risk of bruising/bleeding and jaundice in the range of estimated hepatocytes loss associated with GSK2881078. DILIsym ® analyses of therapeutic doses of acetaminophen or heparin-induced ALT elevations have predicted similar levels of hepatocyte loss in these drugs do not cause clinically significant liver injury when taken as directed. The potential for hepatotoxicity remains an important safety concern that will continue to be monitored closely as we continue to the next stage of clinical development. The doses being taken forward to phase 2a are 2 mg and 1 mg in male and female patients, respectively, which are lower than the highest (4 mg) dose studied that was associated with proportionately more ALT elevations in males in the current study.
Context of HDL decrease
All subjects dosed with GSK2881078 exhibited a reversible reduction in HDL cholesterol. This reduction exhibited evidence of maximal pharmacology at a reduction of 30% to 45% from baseline. This degree of HDL lowering is consistent with reports for other SARMs, but, to our knowledge, this is the first study to conclusively demonstrate a saturable effect of a SARM on HDL suppression. That we observed a plateau in HDL lowering over the dose range suggests enhanced turnover of HDL rather than an effect on its synthesis. Also note that anabolic steroids have been associated with increased levels of the HDL catabolic enzyme hepatic lipase, and this will be the subject of a separate report (to be reported separately).
Context of testosterone decrease
Consistent with other SARMs and androgenic steroids, dosing with GSK2881078 produced reversible reductions in levels of testosterone in men. This was also matched by reductions in sex hormone-binding globulin, but not with clinically significant changes in FSH, LH, estradiol, or progesterone. The mechanism of testosterone suppression is not fully understood, particularly in the context of unchanged LH. Preclinical studies with GSK2881078 confirmed that the compound crosses the blood-brain barrier, but, unlike testosterone (9), it does not appear to influence the hypothalamicpituitary axis to decrease LH secretion. No symptomatic or clinical signs of virilization in females were reported up to 56 days. However, we did not assay for testosterone in female volunteers, and further work will be needed to study the risk of virilization during longer exposure periods.
In summary, GSK20881078 was found to produce potentially clinically significant increases in lean mass, with a differential dose response between sexes. Changes in clinical chemistry were consistent with those previously reported for other SARMs and were relatively mild, monitorable, and reversible in nature. Further research is now planned to study the effects of the compound in patients with both chronic and acute disease states, with additional measures to assess the functional implications of the lean mass gains observed.
